IRLAB Therapeutics: Moving forward with mesdopetam - ABG

Scientific advisory meetings with country-level EU authorities
Market research shows payer interest
Meta-analysis of mesdopetam Ph 2 studies at MDS congress


Meetings with regulatory authorities confirm Ph 3 design

Today IRLAB announced progress with the mesdopetam Ph 3 programme. While the company did not find a mesdopetam partner yet, they continue talks to regulatory authorities in Germany (GER) and Portugal (PT), to align on the design of the planned Ph 3 programme. The country-level regulatory authorities agreed with the FDA-proposed mesdopetam Ph 3 design, as outlined previously. The next step for IRLAB will be interactions with the EMA.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/irlab-therapeutics/Equity-research/2024/10/irlab-therapeutics---moving-forward-with-mesdopetam/